

CBO's Estimate of the Statutory Pay-As-You-Go Effects of H.R. 1570, the Removing Barriers to Colorectal Cancer Screening Act of 2020, as posted on the website, Bills to be Considered on the House Floor (<https://docs.house.gov/floor>) on December 4, 2020 (version H1570_SUS.XML)

	By Fiscal Year, Millions of Dollars										2021-2025	2021-2030
	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030		
	Net Increase or Decrease (-) in the Deficit											
Pay-As-You-Go Effects	-130	-220	-240	-161	-173	-75	-2	121	246	452	-924	-182

Staff Contacts: Cornelia Hall and Lara Robillard

The Statutory Pay-As-You-Go Act of 2010 established budget-reporting procedures for legislation affecting direct spending or revenues. The changes in outlays that are subject to those procedures are shown here. Estimates are relative to CBO's March 2020 baseline and assume enactment at the end of the calendar year. Components may not sum to totals because of rounding.

H.R. 1570 would reduce cost sharing for Medicare beneficiaries for some colorectal cancer screening tests. It would also require manufacturers to report data on average sales prices for prescription drugs paid under Medicare Part B, and then use those data to set Medicare's payment rates for those products. CBO estimates that using those data would reduce Medicare's payments, on average.